NFJ Investment Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

NFJ Investment Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.89M	Hold	67,991	–	–	0.13%	115
2026 Q1	$3.84M	Hold	67,991	–	–	0.15%	120
2025 Q4	$4.04M	Sell	67,991 -1,862	-3%	-$101K	0.15%	121
2025 Q3	$3.78M	Sell	69,853 -1,165	-2%	-$66.6K	0.13%	138
2025 Q2	$3.9M	Sell	71,018 -471	-0.7%	-$27.7K	0.14%	144
2025 Q1	$5.05M	Buy	+71,489	New	+$4.81M	0.17%	133

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

NFJ Investment Group's BMRN Position: Q2 2026 in Review

NFJ Investment Group held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 67,991 shares worth $3.89M. The position accounts for 0.13% of the portfolio, ranked #115.

NFJ Investment Group first reported a position in BMRN in Q1 2025 and has held it in 6 quarters since. The position peaked at $5.05M in Q1 2025. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

NFJ Investment Group held 67,991 shares of BioMarin Pharmaceuticals worth $3.89M as of Q2 2026.
NFJ Investment Group left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up 0.13% of NFJ Investment Group's portfolio in Q2 2026, its #115 holding.
NFJ Investment Group first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
NFJ Investment Group's BioMarin Pharmaceuticals position peaked at $5.05M in Q1 2025.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on NFJ Investment Group's 13F filing for Q2 2026, filed 11 Aug 2026.